An implication of these results is that TGF-β1/collagen inhibitor administration to pancreatic cancer patients might reverse the ability of pancreatic cancer cells to bypass the growth-restraining properties of tumor-associated desmoplasia. The gene discussed is TGFB1; the disease is neoplasm.